Document Detail


A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors.
MedLine Citation:
PMID:  16420567     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM: A multicenter randomized open-label crossover prospective trial was designed to compare the efficacy, safety, and cost of standard and high dosages of recombinant factor VIIa (rFVIIa) for home treatment of hemarthroses in hemophiliacs with inhibitors. METHODS: Patients were instructed to treat, within 6 h from the onset of bleeding, four consecutive hemarthroses of ankles, knees, or elbows, either with the rFVIIa standard dose of 90 microg kg(-1) (repeated as necessary every 3 h) or with a single high dose of 270 microg kg(-1). Patients who did not achieve a clinical success within 9 h continued rFVIIa treatment with repeated standard doses. Response to treatment was assessed for up to 48 h by patients/caregivers, who reported on a Visual Analogue Scale (VAS) graded from 0 to 100 the improvement in symptoms and also rated the responses as effective, partially effective or ineffective. Success was defined a treatment course rated as effective and with a VAS score > or =70 and failure a treatment course rated as ineffective and VAS score < or =30, whereas treatment courses that did not fulfill these criteria were considered partial responses. RESULTS: Twenty hemophiliacs with inhibitors were originally enrolled (median age: 27 years), 18 of them treated 32 hemarthroses assigned to the standard-dosage and 36 to the high-dosage regimen, during the study period of 18 months. Forty-eight hemarthroses (71%) occurred in target joints. Success rates for standard- and high-dosage regimens were similar: 31% and 25% at 9 h, 53% and 50% at 24 h, 66% and 64% at 48 h, the end point for outcome assessment. The median number of rFVIIa infusions needed to achieve a successful course was significantly greater for the standard-dosage (n = 3) than for the high-dosage regimen (n = 1), and the median amount of rFVIIa ultimately used per successful course was identical (270 microg kg(-1)). CONCLUSION: Our results indicate that a high-dosage regimen with rFVIIa for home treatment of hemarthroses is effective, safe, does not imply an increased consumption of rFVIIa and requires the infusion of a smaller number of rFVIIa doses. Its convenience is particularly relevant in cases with difficult venous access and in hemorrhages into target joints.
Authors:
E Santagostino; M E Mancuso; A Rocino; G Mancuso; F Scaraggi; P M Mannucci
Related Documents :
15746637 - Recombinant factor viia use in cardiac surgery--expanding the arsenal therapy for intra...
16207107 - Challenge and rechallenge: drotrecogin alfa (activated)-induced prolongation of activat...
11289287 - Injection treatment of hemorrhoids in patients with acquired immunodeficiency syndrome.
17883557 - Teenage and adult tonsillectomy: dose-response relationship between diathermy energy us...
23288047 - Total knee arthroplasty after high tibial osteotomy: a comparison of opening and closin...
17221327 - The duration of anticoagulation bridging therapy in clinical practice may significantly...
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of thrombosis and haemostasis : JTH     Volume:  4     ISSN:  1538-7933     ISO Abbreviation:  J. Thromb. Haemost.     Publication Date:  2006 Feb 
Date Detail:
Created Date:  2006-01-19     Completed Date:  2006-04-10     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  101170508     Medline TA:  J Thromb Haemost     Country:  England    
Other Details:
Languages:  eng     Pagination:  367-71     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine and Dermatology, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital, Mangiagalli and Regina Elena Foundation and University of Milan, Milan, Italy. hemophilia_ctr@policlinico.mi.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Child
Child, Preschool
Cross-Over Studies
Factor VIIa / administration & dosage,  adverse effects,  antagonists & inhibitors,  therapeutic use*
Hemarthrosis / drug therapy*,  etiology*
Hemophilia A / complications,  drug therapy*
Humans
Infant
Male
Middle Aged
Prospective Studies
Recombinant Proteins / administration & dosage,  adverse effects,  therapeutic use
Safety
Chemical
Reg. No./Substance:
0/Recombinant Proteins; EC 3.4.21.21/Factor VIIa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Activated protein C resistance -- in the absence of factor V Leiden -- and pregnancy.
Next Document:  Thrombin generation time is a novel parameter for monitoring enoxaparin therapy in patients with end...